edivoxetine + propranolol

Edivoxetine (LY2216684) is a potent and highly selective norepinephrine reuptake inhibitor (NRI) that was developed by Eli Lilly as an adjunctive treatment for major depressive disorder (MDD). Propranolol is a non-selective beta-adrenergic receptor antagonist commonly used to treat cardiovascular conditions such as hypertension and arrhythmias. The combination of edivoxetine and propranolol was primarily investigated in clinical pharmacology studies to evaluate the cardiovascular safety profile of edivoxetine. NRIs are known to cause increases in heart rate and blood pressure due to increased sympathetic tone; researchers used propranolol to determine if beta-blockade could attenuate these edivoxetine-induced heart rate increases. Although edivoxetine reached Phase 3 clinical trials, its development was discontinued in 2013 after failing to meet primary efficacy endpoints in late-stage studies for MDD.

Other names

edivoxetine + propranololLY2216684 + propranololedivoxetine hydrochloride + propranolol